Targovax ASA: ASCO abstract released
Oslo, Norway, 18 May 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that the abstract "A Phase I/II trial of TG01/GM-CSF and gemcitabine as adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas" will be presented at the American Society of Clinical Oncology Annual Meeting 2017 (ASCO). The abstract includes clinical data from the phase I/II clinical trial evaluating TG01 in resected pancreatic cancer and